Purpose Gemcitabine and capecitabine (gem-cap), gemcitabine and erlotinib (gem-e), and
folfirinox (5-fluorouracil–leucovorin–irinotecan–oxaliplatin) are new treatment options for
metastatic pancreatic cancer, but they are also more expensive and potentially more toxic
than gemcitabine alone (gem). We conducted a cost-effectiveness analysis of these
treatment options compared with gem. Methods A Markov model was constructed to
examine costs and outcomes of gem-cap, gem-e, folfirinox, and gem in patients with …

6114 Background: Metastatic pancreatic cancer (MPC) is an aggressive disease with a
median survival of 6 months when treated with gemcitabine (G). Gemcitabine+ capecitabine
(G+ C), gemcitabine+ erlotinib (G+ E), and FOLFIRINOX (FFX) are emerging as new
treatment options. However, these new treatment options are costly and it is unclear which is
the most cost-effective. Methods: A Markov model was constructed for a hypothetical cohort
of patients with MPC to examine the costs and outcomes of 4 treatment options (G, G+ C, G+ …